Skip to main content
main-content

Zeitschrift

Cancer Immunology, Immunotherapy

Cancer Immunology, Immunotherapy 6/2016

Ausgabe 6/2016

Inhaltsverzeichnis ( 12 Artikel )

02.05.2016 | Review | Ausgabe 6/2016

Strategies to genetically engineer T cells for cancer immunotherapy

Timothy T. Spear, Kaoru Nagato, Michael I. Nishimura

28.03.2016 | Original Article | Ausgabe 6/2016 Open Access

Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma

Fergus Noble, Toby Mellows, Leo H. McCormick Matthews, Adrian C. Bateman, Scott Harris, Timothy J. Underwood, James P. Byrne, Ian S. Bailey, Donna M. Sharland, Jamie J. Kelly, John N. Primrose, Surinder S. Sahota, Andrew R. Bateman, Gareth J. Thomas, Christian H. Ottensmeier

31.03.2016 | Original Article | Ausgabe 6/2016

2′–5′ Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons

Chan Kyu Sim, Yeon Sook Cho, Byung Soo Kim, In-Jeoung Baek, Young-Joon Kim, Myeong Sup Lee

31.03.2016 | Original Article | Ausgabe 6/2016

Endostatin inhibits the growth and migration of 4T1 mouse breast cancer cells by skewing macrophage polarity toward the M1 phenotype

Hua Guo, Yanan Liu, Junlian Gu, Yue Wang, Lianqin Liu, Ping Zhang, Yang Li

31.03.2016 | Original Article | Ausgabe 6/2016

Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands

Johanna C. Klein, Clarissa A. Wild, Stephan Lang, Sven Brandau

06.04.2016 | Original Article | Ausgabe 6/2016 Open Access

Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer

Federica Cappuccini, Stephen Stribbling, Emily Pollock, Adrian V. S. Hill, Irina Redchenko

15.04.2016 | Original Article | Ausgabe 6/2016

Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma

Eishiro Mizukoshi, Tatsuya Yamashita, Kuniaki Arai, Takeshi Terashima, Masaaki Kitahara, Hidetoshi Nakagawa, Noriho Iida, Kazumi Fushimi, Shuichi Kaneko

20.04.2016 | Original Article | Ausgabe 6/2016

Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion

Stephanie Du Four, Sarah K. Maenhout, Daphné Benteyn, Brenda De Keersmaecker, Johnny Duerinck, Kris Thielemans, Bart Neyns, Joeri L. Aerts

29.04.2016 | Original Article | Ausgabe 6/2016

Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells

Akhil Chawla, Gheath Alatrash, Anne V. Philips, Na Qiao, Pariya Sukhumalchandra, Celine Kerros, Iulia Diaconu, Victor Gall, Samantha Neal, Haley L. Peters, Karen Clise-Dwyer, Jeffrey J. Molldrem, Elizabeth A. Mittendorf

09.05.2016 | Original Article | Ausgabe 6/2016 Open Access

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma

Paula Kroon, Jules Gadiot, Marlies Peeters, Alessia Gasparini, Marcel A. Deken, Hideo Yagita, Marcel Verheij, Jannie Borst, Christian U. Blank, Inge Verbrugge

11.04.2016 | Letter to the Editors | Ausgabe 6/2016

A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome

Elizabeth Hansen, Deepak Sahasrabudhe, Lynn Sievert

19.05.2016 | Letter to the Editors | Ausgabe 6/2016

Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors “A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome”

Lavinia Spain, James Larkin, Juan Martin-Liberal

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise